• TechCrunch
• CrunchBase
• More
  • TechCrunch Europe
  • TechCrunch France
  • TechCrunch Japan

Visterra

edit

Visterra, Inc. engages in pharmaceutical drug research and development of therapeutic and diagnostic products for infectious diseases. It also provides structure-based design of therapeutics and diagnostic platforms, based on an understanding of glycobiology and glycochemistry. The company was formerly known as Parasol Therapeutics, Inc. and changed its name in May 2010. Visterra, Inc. was founded in 2007 and is based in Cambridge, Massachusetts.

Recent Milestones

edit

• 
  Visterra received $13M in Series A funding. (11/9/12)
  Posted 11/10/12 at 2:07am via pehub.com
• 
  Visterra received $12.9M in Venture Round funding. (5/29/12)
  Posted 5/29/12 at 5:53pm via masshightech.com
• 
  Visterra received $6M in Series A funding. (8/10/10)
  Posted 8/10/10 at 5:13pm via onbiovc.com
• 
  Visterra added Donna Ambrosino as Chief Medical Officer.
  Posted 11/10/12 at 2:08am
• 
  Visterra added Mark Boshar as Vice President, Legal.
  Posted 11/10/12 at 2:08am
• 
  Visterra added Steven Brugger as Chief Executive Officer.
  Posted 11/10/12 at 2:08am

Videos

Screenshots

edit

Sources

1. Visterra, Inc.: Series A $6M (onbiovc.com) [edit]
2. Visterra raises $12.9M (masshightech.com) [edit]
3. Visterra Adds $13M to Wrap Up Series A (pehub.com) [edit]